CO2022014388A2 - Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas - Google Patents
Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estasInfo
- Publication number
- CO2022014388A2 CO2022014388A2 CONC2022/0014388A CO2022014388A CO2022014388A2 CO 2022014388 A2 CO2022014388 A2 CO 2022014388A2 CO 2022014388 A CO2022014388 A CO 2022014388A CO 2022014388 A2 CO2022014388 A2 CO 2022014388A2
- Authority
- CO
- Colombia
- Prior art keywords
- therapy
- nirogacestat
- bcma
- combination therapy
- subject
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title 1
- 229950001637 nirogacestat Drugs 0.000 title 1
- 238000002626 targeted therapy Methods 0.000 title 1
- LXEYYZYDWLAIPW-KBVFCZPLSA-N (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide dihydrobromide Chemical group Br.Br.CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C LXEYYZYDWLAIPW-KBVFCZPLSA-N 0.000 abstract 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 1
- 208000023761 AL amyloidosis Diseases 0.000 abstract 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014388A2 true CO2022014388A2 (es) | 2023-02-16 |
Family
ID=75396879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014388A CO2022014388A2 (es) | 2020-03-13 | 2022-10-10 | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (enExample) |
| EP (1) | EP4132515A1 (enExample) |
| JP (2) | JP7781764B2 (enExample) |
| KR (1) | KR20230009873A (enExample) |
| CN (1) | CN115916188A (enExample) |
| AR (1) | AR121566A1 (enExample) |
| AU (1) | AU2021236340A1 (enExample) |
| BR (1) | BR112022018251A2 (enExample) |
| CA (1) | CA3171267A1 (enExample) |
| CL (1) | CL2022002479A1 (enExample) |
| CO (1) | CO2022014388A2 (enExample) |
| IL (1) | IL296075A (enExample) |
| MX (1) | MX2022011258A (enExample) |
| PE (1) | PE20230614A1 (enExample) |
| TW (1) | TW202200132A (enExample) |
| WO (1) | WO2021183934A1 (enExample) |
| ZA (1) | ZA202209989B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311128A (en) | 2021-09-01 | 2024-04-01 | Springworks Therapeutics Inc | Synthesis of neurogestate |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| AU2022396239A1 (en) * | 2021-11-23 | 2024-06-06 | Assia Chemical Industries Ltd. | Solid state forms of nirogacestat salts |
| AU2023271953A1 (en) * | 2022-05-20 | 2024-12-19 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| CN120813574A (zh) * | 2023-03-09 | 2025-10-17 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| EP3662909A1 (en) * | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| IL268349B2 (en) * | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| RU2732196C1 (ru) | 2017-05-05 | 2020-09-14 | Хуавей Текнолоджиз Ко., Лтд. | Способ, устройство и система передачи вспомогательных данных |
| BR112020008812A2 (pt) * | 2017-11-06 | 2020-10-27 | Juno Therapeutics Inc | combinação de terapia celular e um inibidor de gama secretase |
| US11970542B2 (en) * | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
| TWI753229B (zh) * | 2018-01-17 | 2022-01-21 | 美商明塞特製藥公司 | 用於治療癌症之組合療法 |
| MX2020012561A (es) * | 2018-05-24 | 2021-01-29 | Ayala Pharmaceuticals Inc | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas. |
| BR112020024351A2 (pt) * | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| US20220168417A1 (en) * | 2019-04-10 | 2022-06-02 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with an anti bcma antibody and a gamma secretase inhibitor |
| CN114555562A (zh) | 2019-08-09 | 2022-05-27 | 辉瑞公司 | (s)-2-(((s)-6,8-二氟-1,2,3,4-四氢萘-2-基)氨基)-n-(1-(2-甲基-1-(新戊基氨基)丙-2-基)-1h-咪唑-4-基)戊酰胺的固态形式及其用途 |
-
2021
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
-
2022
- 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230009873A (ko) | 2023-01-17 |
| JP2023517243A (ja) | 2023-04-24 |
| CN115916188A (zh) | 2023-04-04 |
| JP7781764B2 (ja) | 2025-12-08 |
| AU2021236340A1 (en) | 2022-09-29 |
| MX2022011258A (es) | 2023-01-11 |
| BR112022018251A2 (pt) | 2022-11-08 |
| IL296075A (en) | 2022-11-01 |
| ZA202209989B (en) | 2025-12-17 |
| US20230121547A1 (en) | 2023-04-20 |
| TW202200132A (zh) | 2022-01-01 |
| PE20230614A1 (es) | 2023-04-14 |
| EP4132515A1 (en) | 2023-02-15 |
| CA3171267A1 (en) | 2021-09-16 |
| AR121566A1 (es) | 2022-06-15 |
| WO2021183934A1 (en) | 2021-09-16 |
| CL2022002479A1 (es) | 2023-08-18 |
| JP2025168430A (ja) | 2025-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014388A2 (es) | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas | |
| ES2527775T3 (es) | Terapia de combinación de un anticuerpo anti-CD20 de tipo II con un inhibidor de proteasoma | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2022002244A (es) | Metodo para identificar respondedores a degradantes de smarca2/4. | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
| PE20211266A1 (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas | |
| CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| PE20120998A1 (es) | Metodos para el tratamiento del cancer usando antagonistas de notch | |
| CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| ECSP23019525A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| MX2020004179A (es) | Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso. | |
| MX2022005031A (es) | Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas. | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2023014500A (es) | Medicamento para el tratamiento y/o prevencion de cancer. | |
| MX2024003258A (es) | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. |